| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | EVP and CCO
3 companies
Michael J. Yang is Director at PCRX and has filed Form 4s across 3 companies. Michael J. Yang's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.2M at current prices.
The biggest single holding is PCRX (~$720K) as Director. Net of sales, the PCRX filings show accumulation of 2,000 shares.
Michael J. Yang has 26 Form 4 filings on record from March 2017 to July 2026, across 3 companies: Director at Ionis Pharmaceuticals (IONS), 2023–2026; Director at Pacira BioSciences (PCRX), 2023–2026; EVP and CCO at Acadia Pharmaceuticals (ACAD), 2017–2021.
The 48 reported transactions were 20 option or other derivative awards, 14 option exercises, 10 open-market sales and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $26K and 7 sales worth about $7.2M.
The only open-market purchase was 2,000 shares of PCRX at an average $12.90 on August 14, 2024, about $26K. Twelve months later PCRX was up 100%.
The largest open-market sale was 105,479 shares of ACAD at an average $44.46 on December 12, 2019, about $4.7M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2024 | PCRX Pacira Biosciences, Inc. | Director | Buy | 2,000 | $12.90 | $25,800.00 | +38.2% | +34.7% | +100.4% | |
| Jan 6, 2021 | ACAD Acadia Pharmaceuticals Inc | EVP and CCO | Sale+OE | 1,120 | $53.34 | $59,740.80 | -12.2% | - | - | |
| Oct 16, 2020 | ACAD Acadia Pharmaceuticals Inc | EVP and CCO | Sale+OE | 1,247 | $42.56 | $53,072.32 | -16.2% | - | - | |
| Jul 7, 2020 | ACAD Acadia Pharmaceuticals Inc | EVP and CCO | Sale+OE | 27,250 | $56.25 | $1,532,786.37 | -84.0% | - | - | |
| Apr 30, 2020 | ACAD Acadia Pharmaceuticals Inc | EVP and CCO | Sale+OE | 1,501 | $49.21 | $73,864.21 | -22.4% | - | - | |
| Dec 12, 2019 | ACAD Acadia Pharmaceuticals Inc | EVP and CCO | Sale+OE | 105,479 | $44.46 | $4,689,262.89 | -97.7% | - | - | |
| Dec 9, 2019 | ACAD Acadia Pharmaceuticals Inc | EVP and CCO | Sale+OE | 14,521 | $50.46 | $732,792.26 | -89.9% | - | - | |
| Oct 15, 2019 | ACAD Acadia Pharmaceuticals Inc | EVP and CCO | Sale+OE | 877 | $39.65 | $34,773.05 | -35.1% | - | - |